{"id":541355,"date":"2010-04-23T00:01:56","date_gmt":"2010-04-23T04:01:56","guid":{"rendered":"http:\/\/www.xconomy.com\/?p=75346"},"modified":"2010-04-23T00:01:56","modified_gmt":"2010-04-23T04:01:56","slug":"genzyme-expects-to-pay-175m-to-fda-westphal-leaves-sirtris-to-run-gsk-venture-arm-gelesis-obesity-treatment-passes-first-human-trial-more-boston-area-life-sciences-news","status":"publish","type":"post","link":"https:\/\/mereja.media\/index\/541355","title":{"rendered":"Genzyme Expects to Pay $175M to FDA, Westphal Leaves Sirtris to Run GSK Venture Arm, Gelesis Obesity Treatment Passes First Human Trial, & More Boston-Area Life Sciences News"},"content":{"rendered":"\n
Roundup<\/a>, Life Sciences<\/a>, Biotech<\/a><\/div>\n

\t\tErin Kutz wrote:<\/strong><\/p>\n

Headlines from both long-established pharma companies and stealthy biotech startups made it a busy life sciences news week for us.<\/p>\n

—It was a life sciences-focused week for us, with the introduction of our new life sciences columnist, Sylvia Pag\u00e1n Westphal<\/a>, a journalist who’s covered biotech for big-name publications. Her inaugural post<\/a> likened the lack of disclosure behind the recent Goldman Sachs scandal to the self-interest that’s fueled myriad missteps in life sciences companies.<\/p>\n

—Hygeia Therapeutics, a Holden, MA-based maker of topical medicine, raised $1 million in Series A funding<\/a> to go toward testing a topical synthetic estrogen drug to treat age-related skin thinning, and developing an anti-androgen.<\/p>\n

—Cambridge-based Javelin Pharmaceuticals (AMEX: JAV<\/a>), a developer of pain treatments, accepted a $145 million buyout offer from specialty drugmaker Hospira, nixing a previous merger agreement with Myriad Pharmaceuticals <\/a>(NASDAQ: MYRX<\/a>). Lake Forest, IL-based Hospira (NYSE:HSP<\/a>) plans to pay $2.20 per share for Javelin common stock, and will also loan the company money to repay loans from Myriad and cover expenses related to breaking the agreement.<\/p>\n

—Dyax, a Cambridge drug developer, will collect as much as $12 million from Paul Capital Healthcare<\/a> for selling the rights to royalties and fees from its hemophilia treatment, with $10 million upfront and up to $2 million in milestone payments related to the drug’s sales.<\/p>\n

—Luke took a closer look at Catabasis Pharmaceuticals, a seven-person Cambridge startup that’s developing drugs to treat inflammation diseases<\/a>, particularly diabetes. He first broke the news last week that the stealthy company had pulled in $7.7 million<\/a> of a planned $39.6 million Series A round from SV Life Sciences, Clarus Ventures, and MedImmune Ventures; the company said it will get the remaining funding if it meets certain development goals.<\/p>\n

—HemaQuest Pharmaceuticals, a biotech founded in Newton, MA that moved to Seattle sometime last year, announced it completed a $12 million Series B funding round<\/a>. New investors Aberdare Ventures, of San Francisco, led the round, which also included a slew of returning backers and will go to …Next Page »<\/a><\/span><\/p>\n

Comments<\/a> | Reprints<\/a> | Share:  
\n\"Retweet\"\/<\/a>
\n \"Facebook\"\/<\/a>
\n \"Email\"\/<\/a>
\n \"Share\"\/<\/a>\n<\/div>\n

UNDERWRITERS AND PARTNERS
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t<\/a>
\n\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t<\/a>
\n\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t<\/a>
\n\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t<\/a>
\n\t\t\t\t\t\t<\/p>\n

\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t<\/a>
\n\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t<\/a>
\n\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t<\/a>
\n\t\t\t\t\t\t\t\t\t

\n

\n\"\"<\/a>
\n\"\"<\/p>\n

<\/img><\/a>
\n<\/img><\/a><\/p>\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Roundup, Life Sciences, Biotech Erin Kutz wrote: Headlines from both long-established pharma companies and stealthy biotech startups made it a busy life sciences news week for us. —It was a life sciences-focused week for us, with the introduction of our new life sciences columnist, Sylvia Pag\u00e1n Westphal, a journalist who’s covered biotech for big-name publications. […]<\/p>\n","protected":false},"author":1661,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-541355","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/541355","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/users\/1661"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/comments?post=541355"}],"version-history":[{"count":0,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/541355\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/media?parent=541355"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/categories?post=541355"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/tags?post=541355"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}